Results 41 to 50 of about 21,604,258 (289)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

open access: yesClinical Case Reports, 2020
The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.
Francesco Paolo Tambaro   +8 more
doaj   +1 more source

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

open access: yesFrontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong   +33 more
doaj   +1 more source

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity

open access: yesCells, 2021
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj   +1 more source

Chimeric antigen receptor T‐cell therapies: Optimising the dose [PDF]

open access: yesBritish Journal of Clinical Pharmacology, 2020
Lymphocytes such as T‐cells can be genetically transduced to express a synthetic chimeric antigen receptor (CAR) that re‐directs their cytotoxic activity against a tumour‐expressed antigen of choice. Autologous (patient‐derived) CAR T‐cells have been licensed to treat certain relapsed and refractory B‐cell malignancies, and numerous CAR T‐cell products
Nathaniel Dasyam   +2 more
openaire   +2 more sources

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

open access: yesCell Transplantation, 2022
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang   +7 more
doaj   +1 more source

Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.

open access: yes, 2022
Chimeric antigen receptor (CAR) T-cells targeting CD19 have drastically improved the outcomes of B-cell malignancies; however, the success has not yet extended to myeloid malignancies such as acute myeloid leukemia (AML).
Gergis, Usama, MD, MBA   +5 more
core   +3 more sources

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors [PDF]

open access: yesTrends in Pharmacological Sciences, 2016
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors.
Daniel T, Harris, David M, Kranz
openaire   +2 more sources

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma

open access: yes, 2022
Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients.
Mingming Zhang   +7 more
core   +1 more source

Antibody-conjugated lipid nanoparticles for in vivo CAR-T cell engineering: From concept to clinical translation

open access: yesNano Biomedicine and Engineering
Chimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj   +1 more source

Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular Cloning

open access: yes, 2022
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular ...
Anthony J Bais (13285305)
core   +1 more source

Home - About - Disclaimer - Privacy